UI Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine versus Trastuzumab as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer who have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy
Description

Participants in this study have HER2-positive primary non-metastatic breast cancer and had evidence of cancer in breast and lymph nodes after chemotherapy. Participants will receive either trastuzumab emtansine, (previously known as T-DM1) or Trastuzumab alone. Trastuzumab emtansine is an investigational drug, which means that health authorities have not approved trastuzumab emtansine for the treatment of HER2-positive primary non-metastatic breast cancer. The purpose of this research study is to find out the effects of trastuzumab emtansine versus trastuzumab and which is more effective in treating breast cancer.

Start Date
July 3, 2013
End Date
August 1, 2023
Gender Preference
None
Age Group
18 - 99 years
Principal Investigator
Alexandra Thomas, MD
Contact Info

Michelle Arnold 319-356-2778

Department
Keywords
breast cancer ; cancer ; phase III ; phase three ; thomas ; trastuzumab ; trastuzumab emtansine (T-DM1) ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.